Rosiglitalozone produces a greater reduction in circulating platelet activity compared with glicazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPARgamma activation - Khanolkar, MP; Morris, RH; Thomas, AW (Atherosclerosis, 2008)
et al.